Medications for Opioid Use Disorder (MOUD), including buprenorphine, methadone, and naltrexone, remain the gold standard for treating opioid use disorder (OUD) and reducing overdose mortality. Extensive research demonstrates that MOUD significantly reduces illicit opioid use, lowers overdose risk, improves treatment retention, and enhances long-term recovery outcomes (National Institute on Drug Abuse [NIDA], 2023). Despite this evidence, substantial racial disparities persist in access to and utilization of MOUD, particularly among Black individuals and historically marginalized communities.
Black communities continue to experience some of the fastest rising overdose death rates in the
United States while simultaneously facing reduced access to evidence-based treatment interventions (Centers for Disease Control and Prevention [CDC], 2023). These disparities are not attributable to individual behavior alone but rather reflect longstanding structural inequities embedded within healthcare systems, insurance access, prescribing practices, criminal legal system involvement, and broader social determinants of health.
Historically, substance use within Black communities has been framed through criminalization rather than treatment. During the crack cocaine epidemic of the 1980s and 1990s, public policy responses emphasized incarceration, punitive sentencing, and aggressive policing rather than healthcare intervention or recovery-oriented support (Mauer & Chesney-Lind, 2002). In contrast, the opioid epidemic affecting predominantly white communities was more frequently framed as a public health issue requiring treatment access, compassion, and medical intervention. These racialized policy responses continue to influence treatment access patterns today.
Research consistently demonstrates that Black individuals are significantly less likely than white individuals to receive buprenorphine treatment, even when presenting with similar clinical need and treatment readiness (Hollander et al., 2021). Provider bias, healthcare mistrust, fragmented care systems, transportation barriers, insurance disruptions, and reduced availability of low- barrier treatment programs all contribute to inequitable access.
For justice-impacted individuals, these barriers are intensified during the reentry period following incarceration. The immediate post-release period is associated with dramatically elevated overdose risk due to reduced opioid tolerance, unstable housing, fragmented healthcare access, and limited continuity of care (Binswanger et al., 2007). Individuals often return to communities without active Medi-Cal coverage, coordinated discharge planning, or linkage to community-based treatment providers.
In practice settings serving justice-impacted and historically marginalized populations, barriers to MOUD are often less about whether treatment exists and more about whether systems are perceived as trustworthy, accessible, and responsive to lived realities. Many participants entering treatment have experienced repeated cycles of criminalization, institutional exclusion, interrupted healthcare access, and punitive responses to substance use. As a result, engagement frequently depends on whether individuals perceive systems as safe, respectful, and culturally responsive.
Practice-informed implementation experience demonstrates that treatment retention improves when participants are supported through relationship-centered approaches that combine clinical care with peer navigation, culturally responsive engagement, and continuity-of-care support. Peer Recovery Support Navigators often function as the bridge between institutional systems and participant trust, helping individuals navigate barriers that traditional clinical interventions alone may not adequately address.
The Transitions Clinic Network (TCN) model demonstrates that integrating lived-experience staff into healthcare teams improves engagement, strengthens continuity of care, and reduces emergency department utilization among justice-impacted populations (Wang et al., 2012). By incorporating culturally responsive peer navigation into MOUD treatment settings, healthcare systems can begin addressing not only opioid use disorder itself, but also the structural inequities that shape treatment access and recovery outcomes.
Addressing these disparities requires more than increasing treatment capacity alone. It requires redesigning systems around accessibility, trust, cultural responsiveness, and continuity of care. Promising Practice and Emerging Models Emerging healthcare and community-based models demonstrate that culturally responsive, peer- integrated interventions can improve treatment engagement among populations disproportionately impacted by opioid use disorder and systemic inequities.
The Transitions Clinic Network (TCN), developed in partnership with community organizations and individuals impacted by incarceration, is one of the most promising evidence-based models currently addressing opioid use disorder and healthcare inequities among justice-impacted populations. The TCN model embeds Community Health Workers (CHWs) with lived experience of incarceration into primary care settings to improve healthcare engagement, continuity of care, and treatment retention. Research associated with the model demonstrates reductions in emergency department utilization, preventable hospitalizations, parole and probation violations, and criminal legal system costs while improving patient engagement in care.
Importantly, TCN recognizes that opioid use disorder treatment outcomes are inseparable from
broader social determinants of health, including housing instability, food insecurity, transportation barriers, and healthcare mistrust. The model therefore integrates peer support, care coordination, behavioral health engagement, and community-based social support into primary care delivery.
Additional promising approaches include low-barrier buprenorphine programs, mobile harm reduction outreach teams, and Enhanced Care Management models within California’s CalAIM framework that incorporate Peer Recovery Support Navigators and Community Health Workers into multidisciplinary care teams serving high-risk populations.
These emerging models demonstrate that improving MOUD outcomes within Black communities requires not only medication access; but also trust-centered systems capable of addressing structural barriers to care.
References
Binswanger, I. A., Stern, M. F., Deyo, R. A., et al. (2007). Release from prison, a high risk of death for former inmates. New England Journal of Medicine, 356(2), 157–165.
Centers for Disease Control and Prevention. (2023). Drug overdose deaths in the United States. Hollander, M. A. G., Chang, C. H., Douaihy, A. B., & Hulsey, E. G. (2021). Racial inequity in medication treatment for opioid use disorder. Journal of Addiction Medicine, 15(6), 496–505.
Mauer, M., & Chesney-Lind, M. (2002). Invisible punishment: The collateral consequences of mass incarceration. The New Press.
National Institute on Drug Abuse. (2023). Medications to treat opioid use disorder research report.
Wang, E. A., Hong, C. S., Shavit, S., Sanders, R., Kessell, E., & Kushel, M. B. (2012). Engaging individuals recently released from prison into primary care. American Journal of Public Health, 102(9), e22–e29.
